The Masonic Cancer Center (MCC) is an NCI-designated Comprehensive Cancer Center dedicated to cancer research, education, and patient care for the citizens of Minnesota and the surrounding region. Since the time of the first award in 1997, there has been tremendous growth of the membership and research base. In 2013, there are 240 members, up from 225 in 2007 and 98 in 1997. Nationally peer-reviewed support increased from approximately $86 million in 2007 to more than $100 million in 2012. Total MCC research support in 2012 was more than $112M. In 2010, the Minnesota Masonic Charities made a transformational philanthropic donation of $65 million to be spent over 15 years;this has enabled us to enhance faculty recruitment and support, increase the number of pilot projects, and build on translational research efforts. The MCC is organized into 7 programs that focus on specific scientific themes: Prevention and Etiology, Carcinogenesis and Chemoprevention, Genetic Mechanisms of Cancer, Tumor Microenvironment, Immunology, Cell Signaling, and Transplant Biology and Therapy. These programs are supported by 9 shared resources. The past funding period has seen increased emphasis on developing our translational pipeline. Several resources have been put into place to support this effort and to better connect the basic programmatic research with the clinic. These resources include a Cancer Experimental Therapeutics Initiative to increase the number of investigator-initiated clinical trials at MCC, an the formation of translational working groups that bring together researchers, clinicians, and others in the oncology community to solve problems in organ-site-specific cancers. We have also established several mechanisms to increase the involvement of the community, and particularly the underserved populations in our catchment area, in clinical research. The MCC is a successful matrix organization in a large public research university that engages its faculty to focus on the problem of cancer. Our last period of support has been characterized growth, stability in our leadership, enhanced engagement of our community, and creation of several new cancer focused initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA077598-16S2
Application #
8839853
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-06-01
Project End
2019-01-31
Budget Start
2014-03-05
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$49,994
Indirect Cost
$17,103
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Abbott, Kenneth L; Nyre, Erik T; Abrahante, Juan et al. (2015) The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res 43:D844-8
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Daniel, A R; Gaviglio, A L; Knutson, T P et al. (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506-15
Upadhyaya, Pramod; Hecht, Stephen S (2015) Quantitative analysis of 3'-hydroxynorcotinine in human urine. Nicotine Tob Res 17:524-9
Patel, Yesha M; Stram, Daniel O; Wilkens, Lynne R et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 24:119-27
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Chen, Liddy M; Ibrahim, Joseph G; Chu, Haitao (2014) Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. J Biopharm Stat 24:817-33
Takahashi, Yutaka; Hui, Susanta K (2014) Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy. Radiat Oncol 9:34
Gates, Leah A; Phillips, Martin B; Matter, Brock A et al. (2014) Comparative metabolism of furan in rodent and human cryopreserved hepatocytes. Drug Metab Dispos 42:1132-6
Gorden, Brandi H; Kim, Jong-Hyuk; Sarver, Aaron L et al. (2014) Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. Am J Pathol 184:985-95

Showing the most recent 10 out of 319 publications